What it's for (Indications)
- Atropine ophthalmic preparations, such as Ophth-Atropine Ointment, are primarily indicated for use in ophthalmology to achieve potent and prolonged mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle).
- This dual action is crucial for several diagnostic and therapeutic purposes.
- Therapeutically, it is extensively used in the treatment of inflammatory conditions of the iris and ciliary body, such as iritis and uveitis, to prevent the formation of posterior synechiae (adhesions between the iris and lens capsule) and to alleviate ciliary spasm, thereby reducing pain.
- Diagnostically, atropine facilitates thorough examination of the fundus and accurate refraction by temporarily paralyzing accommodation.
- Furthermore, it is a key component in the penalization treatment regimen for amblyopia (lazy eye) in children, where it blurs vision in the stronger eye to encourage the weaker eye to develop.
- The selection of atropine over other cycloplegics is often due to its sustained and profound effect, making it suitable for specific clinical scenarios requiring prolonged pupillary dilation and accommodative paralysis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of atropine ophthalmic preparations, including Ophth-Atropine Ointment 1%, must be carefully determined by an ophthalmologist, considering the patient's age, weight, and the specific clinical indication. For mydriasis and cycloplegia in diagnostic procedures or inflammatory conditions, a common regimen involves applying a small amount of ointment (e.g., a 1 cm strip) to the conjunctival sac of the affected eye once or twice daily, or as directed. When used for amblyopia penalization therapy, the typical dosage is a small amount of 1% ointment or one drop of 1% solution applied to the stronger eye once daily or 2-3 times per week, tailored to achieve appropriate blurring of vision without excessive systemic absorption. It is critical for caregivers to be instructed on the proper technique for ophthalmic ointment application to minimize systemic absorption and ensure maximal local effect. This includes applying pressure to the nasolacrimal duct for at least one minute following application, especially in pediatric patients, to reduce the risk of systemic side effects. Dosage adjustments may be necessary for infants and children due to their increased susceptibility to anticholinergic systemic effects. |
Safety & Warnings
Common Side Effects
- Atropine ophthalmic can cause both local ocular side effects and, due to systemic absorption, more widespread anticholinergic adverse reactions.
- Ocularly, patients commonly experience blurred vision and photophobia (light sensitivity) due to the sustained mydriasis and cycloplegia, which are direct pharmacological actions of the drug.
- Other localized effects can include transient stinging or burning upon instillation, conjunctival hyperemia, follicular conjunctivitis, allergic contact dermatitis of the eyelids, and a temporary increase in intraocular pressure, particularly in predisposed individuals with narrow angles.
- Systemic side effects, though less common with ophthalmic use, can be significant, especially in children, the elderly, or with excessive absorption.
- These include dry mouth (xerostomia), facial flushing, fever (atropine fever, especially in children), tachycardia (rapid heart rate), urinary retention, constipation, and central nervous system disturbances such as restlessness, irritability, disorientation, hallucinations, ataxia, and in severe cases, seizures or coma.
- Parents and patients should be thoroughly educated on recognizing these signs of toxicity.
Serious Warnings
- Black Box Warning: While atropine ophthalmic does not carry a formal FDA "Black Box Warning," clinicians and patients must be fully aware of several serious safety concerns, particularly regarding systemic toxicity. **Serious Warnings:** Potentially life-threatening systemic anticholinergic effects can occur, especially in infants, young children, and the elderly, due to significant systemic absorption following ocular administration. Signs of atropine poisoning include elevated body temperature (fever), facial flushing, severe dry mouth, pronounced tachycardia, urinary retention, abdominal distension, and central nervous system effects such as restlessness, disorientation, hallucinations, seizures, and severe ataxia. Cases of severe systemic toxicity, including fatalities, have been reported, particularly with accidental ingestion or excessive ophthalmic use in pediatric patients. Meticulous care must be exercised in dosage calculation and administration techniques, including effective nasolacrimal occlusion for at least two minutes post-instillation, to minimize systemic absorption. Furthermore, atropine is contraindicated in individuals with narrow-angle glaucoma or a predisposition to it, as its mydriatic action can induce an acute angle-closure attack, which is a medical emergency requiring immediate intervention to prevent permanent vision loss. All patients, especially parents of pediatric patients, must be educated on the symptoms of systemic toxicity and advised to seek immediate medical attention if any occur.
- Several critical warnings are associated with the use of atropine ophthalmic preparations to ensure patient safety and prevent adverse outcomes.
- Systemic absorption of atropine through the nasal mucosa or gastrointestinal tract after lacrimal drainage can lead to significant anticholinergic effects, particularly in infants and young children who are more susceptible to its systemic toxicity.
- This risk necessitates careful dosage calculation and proper instillation techniques, including nasolacrimal occlusion after administration, to minimize systemic uptake.
- Atropine should be used with extreme caution, or preferably avoided, in patients with a history of, or predisposition to, narrow-angle glaucoma, as its mydriatic effect can precipitate an acute angle-closure attack by further narrowing the anterior chamber angle.
- Patients should be advised that the medication will cause prolonged blurring of vision and increased sensitivity to light; therefore, they should avoid driving or operating machinery and wear sunglasses until these effects subside.
- There is also a risk of heat prostration in susceptible individuals (e.
- g.
- , children, elderly) or in hot environments due to the suppression of sweating caused by systemic anticholinergic effects.
- Close monitoring for signs of systemic toxicity is imperative, particularly in vulnerable populations.
How it Works (Mechanism of Action)
Atropine is a potent, non-selective muscarinic acetylcholine receptor antagonist. Its therapeutic effects in ophthalmology stem from its ability to competitively block the action of acetylcholine at postganglionic parasympathetic nerve endings within the eye. Specifically, atropine binds to and inactivates muscarinic receptors located on the sphincter muscle of the iris and the ciliary body. By blocking these receptors on the iris sphincter, atropine prevents pupillary constriction, leading to unopposed dilation of the pupil, a phenomenon known as mydriasis. Concurrently, by blocking muscarinic receptors on the ciliary muscle, it paralyzes the muscle's ability to contract, which results in the loss of accommodation (the eye's ability to focus on near objects), known as cycloplegia. This profound and long-lasting paralysis of both pupillary constriction and accommodation is essential for various diagnostic procedures, such as refraction and fundus examination, and therapeutic interventions, like preventing synechiae formation in uveitis. The duration of these effects can extend for several days, making atropine the longest-acting cycloplegic agent available.